Revenio Group Corporation | Press Release | August 20, 2026 at 15:30:00 EEST
Revenio Group is pleased to invite analysts, investors, and media representatives to its Capital Markets Day on Tuesday, September 15, 2026, at 2:00 p.m EEST. The event will take place in Sanomatalo (Töölönlahdenkatu 2) in Helsinki and can be followed as a live webcast open to everyone.
Revenio completed the acquisition of Visionix in May 2026. Following the acquisition, Revenio has focused on progressing integration and formulating a new combined strategy. At the Capital Markets Day, the company's key personnel will present an in-depth overview of Revenio's strategy.
The detailed program is published on www.reveniogroup.fi/en/investors/CMD2026. The presentation materials and the event recording will be available on the same webpage after the event.
Following the live webcast
Private investors and other interested parties can view the event via live webcast at https://revenio.events.inderes.com/2026-cmd. The language of the event and the materials is English.
It is possible to ask questions from Revenio's management throughout the event via the webcast.
Registration to attend the event in person
Institutional investors, analysts and media representatives are welcome to participate in person at FLIK event studio Eliel. In order to attend the event, please register via email to elina.kari@revenio.fi by Monday, September 7 at the latest. The number of seats is limited.
We warmly welcome you to our Capital Markets Day!
For further information, please contact
CEO Jouni Toijala
+358 50 484 0085
jouni.toijala@revenio.fi
Distribution
Principal media
www.reveniogroup.fi/en/
Revenio Group in brief
Revenio is a leading turnkey solutions provider in the global eye care market. The group offers fast, user-friendly, and reliable tools for diagnosing a wide variety of eye diseases. Revenio’s solutions include e.g. tonometers, fundus imaging devices, optical coherence tomography (OCT), perimeters, multimodal devices, refraction systems, and software solutions under iCare and Visionix.
In May 2026, Revenio joined forces with Visionix, creating the most innovative, creative and comprehensive entity serving eye care professionals across optometry, optical retail and ophthalmology. In 2025, the Group’s net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.